1. Value of the fibrinogen–platelet ratio in patients with resectable pancreatic cancer
- Author
-
Arakawa, Yusuke, Miyazaki, Katsuki, Yoshikawa, Masato, Yamada, Shinichirou, Saito, Yu, Ikemoto, Tetsuya, Imura, Satoru, Morine, Yuji, Shimada, Mitsuo, Arakawa, Yusuke, Miyazaki, Katsuki, Yoshikawa, Masato, Yamada, Shinichirou, Saito, Yu, Ikemoto, Tetsuya, Imura, Satoru, Morine, Yuji, and Shimada, Mitsuo
- Abstract
Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen–platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U / ml, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer.
- Published
- 2021